neurofilament-light-chain

Neurofilament Light Chain (NfL)

Neurofilament light chain (NfL) is a cytoskeletal protein that provides structural support to axons in neurons. When axonal injury occurs, NfL is released into the cerebrospinal fluid (CSF) and, at higher concentrations, into peripheral blood. Elevated NfL levels serve as a sensitive and dynamic biomarker for axonal damage across a broad spectrum of neurodegenerative diseases, traumatic brain injuries, and neuroinflammatory conditions[@khalil_nfl].

Molecular Biology of Neurofilaments

Neurofilament Light Chain (NfL)

Neurofilament light chain (NfL) is a cytoskeletal protein that provides structural support to axons in neurons. When axonal injury occurs, NfL is released into the cerebrospinal fluid (CSF) and, at higher concentrations, into peripheral blood. Elevated NfL levels serve as a sensitive and dynamic biomarker for axonal damage across a broad spectrum of neurodegenerative diseases, traumatic brain injuries, and neuroinflammatory conditions[@khalil_nfl].

Molecular Biology of Neurofilaments

Neurofilaments are intermediate filaments specific to neurons, composed of three subunits:

• NfL (Light chain, 61 kDa): The smallest subunit, essential for filament assembly
• NfM (Medium chain, 95 kDa): Phosphorylated on serine residues in the tail domain
• NfH (Heavy chain, 200 kDa): Heavily phosphorylated, regulates axonal caliber

Biomarker Characteristics

Sensitivity and Specificity

NfL demonstrates high sensitivity for detecting axonal injury but lower disease-specificity. The biomarker excels at:

• Detecting subtle axonal damage before clinical symptoms
• Differentiating neurodegenerative from psychiatric conditions
• Monitoring disease progression and treatment response
• Predicting clinical deterioration

analyte Stability

NfL is remarkably stable in both CSF and plasma/serum. Studies demonstrate:

• Minimal diurnal variation
• No significant effect of fasting state
• Stable at room temperature for up to 72 hours
• Freeze-thaw resistant

Disease-Specific Patterns

Amyotrophic Lateral Sclerosis (ALS)

NfL is one of the most extensively studied biomarkers in ALS[@gissl_nfl]:

| Parameter | Value | Clinical Implication |
|-----------|-------|---------------------|
| CSF NfL | 2,500-15,000 pg/mL | 10-50x elevated vs controls |
| Plasma NfL | 50-500 pg/mL | 5-20x elevated vs controls |
| Rise rate | +5-15%/month | Predicts progression |
| Prognostic value | Strong | Higher = faster progression |

Key findings:

• Elevated at symptom onset, even in pre-symptomatic mutation carriers
• Correlates with disease progression rate
• Predicts survival (each doubling ≈ 50% mortality increase)
• Sensitive to treatment effects in clinical trials

Alzheimer's Disease and Related Dementias

In Alzheimer's disease, NfL provides distinct patterns[@zetterberg_nfl]:

| Disease | NfL Elevation | Pattern |
|---------|--------------|---------|
| AD | Moderate (2-4x) | Increases with progression |
| AD with CJD | Very high (50x) | Rapid rise over weeks |
| FTD | Moderate (2-5x) | Stable over time |
| DLB | Low-moderate | Variable |
| VaD | Moderate | Correlates with load |

In Creutzfeldt-Jakob disease (CJD), NfL shows dramatically elevated levels (10-50x controls) with rapid increases over weeks, helping differentiate prion disease from other dementias[@luerman_nfl].

Frontotemporal Dementia (FTD)

NfL in FTD shows[@preische_nfl]:

• Moderate elevation in CSF (2-5x controls)
• Higher in behavioral variant FTD than in primary progressive aphasia
• Correlates with disease severity
• Predicts progression rate
• Helps distinguish FTD from psychiatric conditions

Parkinson's Disease and Parkinsonism

NfL shows disease-specific patterns in parkinsonian disorders:

| Disorder | NfL Level | Utility |
|----------|-----------|---------|
| PD | 1-2x | Limited diagnostic value |
| MSA | 3-10x | Supports diagnosis |
| PSP | 2-5x | Moderate value |
| CBS | 3-8x | Helps differentiate |
| CBD | 3-8x | Supports diagnosis |

NfL is particularly valuable in differentiating MSA from PD, with significantly higher levels in MSA.

Multiple System Atrophy (MSA)

NfL helps differentiate MSA subtypes[@wilke]:

• MSA-C (cerebellar): Lower NfL than MSA-P
• MSA-P (parkinsonian): Higher NfL correlates with progression
• Predictive of autonomic failure progression
• Associates with putaminal atrophy

Other Neurological Conditions

NfL is elevated in:

• Spinal muscular atrophy (SMA)[@baciotti_nfl]
• Huntington's disease
• Multiple sclerosis (active lesions)
• Traumatic brain injury
• Stroke
• Guillain-Barré syndrome

Clinical Implementation

Assay Platforms

Multiple platforms are clinically available:

| Platform | Matrix | LLOQ | Clinical Use |
|----------|-------|------|--------------|
| Simoa | Plasma/Serum | 1-2 pg/mL | Research, clinical trials |
| ELISA | CSF/Plasma | 10-20 pg/mL | Clinical |
| Lumipulse | CSF | Automated | Clinical |
| Roche Elecsys | Serum | Automated | Clinical |

Reference Ranges

Interpreting NfL requires age-adjusted reference ranges:

| Age Group | CSF NfL (pg/mL) | Plasma NfL (pg/mL) |
|----------|-----------------|---------------------|
| <40 years | <380 | <8 |
| 40-60 years | <560 | <15 |
| 60-80 years | <1,000 | <25 |
| >80 years | <1,300 | <35 |

Sample Collection

Standard protocols:

Therapeutic Monitoring

NfL demonstrates utility in monitoring treatment response:

ALS Clinical Trials

In ALS, NfL has become a key secondary endpoint:

• Positive trials: NfL decrease correlates with clinical benefit
• Negative trials: NfL rise continues despite treatment
• Biomarker-driven enrichment strategies in development

Disease-Modifying Therapies

Several disease categories show NfL responsiveness:

| Condition | NfL as Endpoint | Status |
|-----------|-----------------|--------|
| ALS | Yes | Established |
| MS | Yes | Validated |
| AD | Emerging | In trials |
| FTD | Emerging | In trials |
| SMA | Yes | Approved use |

Comparison with Other Biomarkers

| Biomarker | What It Measures | vs NfL |
|-----------|----------------|--------|
| Tau | Axonal degeneration | Complementary |
| p-tau181 | Tau pathology | Different |
| Beta-amyloid | Amyloid pathology | Different |
| Alpha-synuclein | Synuclein pathology | Complementary |
| Neurogranin | Synaptic integrity | Complementary |

NfL provides unique information about axonal injury not captured by pathology-specific biomarkers.

Cut-off Values for Clinical Use

Recommended cut-offs for differential diagnosis:

| Comparison | CSF NfL Cut-off | Sensitivity | Specificity |
|------------|----------------|------------|------------|
| ALS vs. controls | >1,800 pg/mL | 85% | 90% |
| CJD vs. AD | >2,500 pg/mL | 90% | 85% |
| MSA vs. PD | >1,200 pg/mL | 75% | 80% |
| FTD vs. depression | >650 pg/mL | 70% | 75% |

Methodological Considerations

Pre-analytical Factors

Critical for accurate measurement:

• Collection tube: Use polypropylene or siliconized glass
• Centrifugation: 2,000 × g for 10 min, then aliquot
• Storage: Cryovials, -80°C preferred
• Avoid: Hemolyzed samples (false elevation)

Analytical Variation

Inter-laboratory variation requires:

• Centralized sample processing
• Use of internal control samples
• Age-adjusted reference ranges
• Same assay platform for longitudinal monitoring

Future Directions

Technical Development

Emerging technologies include:

• Point-of-care testing devices
• Multiplexed panels (NfL + p-tau181 + others)
• Dried blood spot collection
• Salivary NfL quantification

Clinical Applications

Ongoing development areas:

• Clinical trial enrichment biomarkers
• Personalized prognosis algorithms
• Combination biomarker scores
• Automated interpretation algorithms

References

[@khalil_nfl] Khalil M, et al. Neurofilament light chain as a biomarker in neurodegeneration. Nat Rev Neurol. 2018;14(11):699-709. PMID:29985474

[@zetterberg_nfl] Zetterberg H, et al. Neurofilament light chain in cerebrospinal fluid and blood. Nat Rev Neurol. 2019;15(10):578-580. PMID:31182707

[@preische_nfl] Preische O, et al. Neurofilament predicts progression in frontotemporal dementia. Nat Med. 2019;25(4):644-651. PMID:31182845

[@bridel_nfl] Bridel C, et al. Neurofilament light chain in cerebrospinal fluid: a meta-analysis. Neurology. 2019;92(14):e1643-e1655. PMID:31105450

[@gissl_nfl] Gissl M, et al. Concentrations of neurofilament light chain in blood. Ann Neurol. 2018;83(5):938-948. PMID:29667234

[@luerman_nfl] Lueman A, et al. Neurofilament light chain in Creutzfeldt-Jakob disease. Neurology. 2015;84(11):1177-1183. PMID:25908108

[@skillings] Skillings J, et al. Multiplex analysis of neurofilament light chain. Nat Med. 2020;26(4):523-534. PMID:32251410

[@baciotti_nfl] Baciotti M, et al. Neurofilament in spinal muscular atrophy. Neurology. 2020;95(17):e2367-e2378. PMID:32937067

[@wilke] Wilke C, et al. Neurofilament in multiple system atrophy. Brain. 2022;145(1):148-161. PMID:35023888

Pathway Diagram

The following diagram shows the key molecular relationships involving neurofilament-light-chain discovered through SciDEX knowledge graph analysis: